Evaluation of bosentan, pinacidil and nitroprusside on human pulmonary arteries: Comparison with rat pulmonary arteries

Fundamental and Clinical Pharmacology

Volumn 11, Issue 6, 1997, Pages 584-591

  Wanstall, J C ^a   Kay, C S ^a   O'Donnell, S R ^a   Wilson, K ^b   Cole, P H ^b   Matar, K ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Endothelin antagonist; Human pulmonary artery; Nitric oxide donor; Potassium channel opening drug; Rat pulmonary artery

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PINACIDIL; POTASSIUM CHANNEL STIMULATING AGENT;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; RAT; VASODILATATION;

EID: 0030670257     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1997.tb00864.x     Document Type: Article

References (28)

1. Angus JA, Cocks TM, Satoh K. α-Adrenoceptors and endothelium-dependent relaxation in canine large arteries. Br J Pharmacol 1986;88:767-78
2. Archer SL, Huang JM-C, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 1994;91:7583-7
3. Archer SL, Huang JM-C, Reeve HL, Hampl V, Tolarova S, Michelakis E, Weir EK. Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia. Circ Res 1996;78:431-42
4. Barnes PJ, Liu SF. Regulation of pulmonary vascular tone. Pharmacol Rev 1995;47:87-131
5. Bialecki RA, Fisher CS, Murdoch WW, Barthlow HG, Bertelsen DL. Functional comparison of endothelin receptors in human and rat pulmonary artery smooth muscle. Am J Physiol 1997;272:L211-18
6. Chen S-J, Chen Y-F, Meng QC, Durand J, DiCario VS, Oparil S. Endothelin receptor antagonist bosentan prevents and reverses hypoxia induced pulmonary hypertension in the rat. J Appl Physiol 1995;79:2122-31
7. Clozel M, Breu V, Gray GA, Kalina B, Loffler B-M, Burri K et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270:228-35
8. Crilley TX, Wanstall JC. A comparative study of inhibitors of phosphodiesterases III and V in pulmonary arteries from pulmonary hypertensive and normotensive rats. Proc Aust Soc Exp Pharmacol Toxicol 1996;3:96
9. Dinh-Xuan AT. Disorders of endothelium-dependent relaxation in pulmonary disease. Circulation 1993;87(suppl V): V81-7
10. Fukuroda T, Osaki S, Iara M, Ishikawa K, Yano M, Nishikibi M. Synergistic inhibition by BQ-123 and BQ-788 of endothelin-induced contractions of the rabbit pulmonary artery. Br J Pharmacol 1994;113:336-8
11. Hay DWP, Luttman MA, Hubbard WC, Undem BJ. Endothelin receptor subtypes in human and guinea-pig pulmonary tissues. Br J Pharmacol 1993;110:1175-83
12. Higashi T, Ishizaki T, Shigemori K, Nakai T, Miyabo S, Inui T, Yamamura T. Pharmacological heterogeneity of constrictions mediated by endothelin receptors in rat pulmonary arteries. Am J Physiol 1997;272:L287-93
13. Higgenbottam TW. The place of prostacyclin in the clinical management of primary pulmonary hypertension. Am Rev Resp Dis 1987;136:782-5
14. Kay CS, Wanstall JC, O'Donnell SR, Wilson K, Matar K. Antagonism of endothelin ETA responses by bosentan in pulmonary arteries from human and rat. Proc Aust Soc Clin Exp Pharmacol Toxicol 1995;2:153
15. Kenakin TP. The Schild regression in the process of receptor classification. Can J Physiol Pharmacol 1982;60:249-65
16. B receptor-mediated contractions of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat. J Cardiovasc Pharmacol 1995;26 (suppl 3):S169-76
17. O'Donnell SR, Kay CS. Effects of endothelin receptor selective antagonists, BQ-123 and BQ-788, on IRL 1620 and endothelin-1 responses of airway and vascular preparations from rats. Pulm Pharmacol 1995;8:11-19
18. Oka M, Morris KG, McMurtry IF. NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension. J Appl Physiol 1993,75:1075-80
19. Oparil S, Chen S-J, Meng QC, Elton TS, Yano M, Chen Y-F. Endothelin-A receptor antagonist prevents acute hypoxiainduced pulmonary hypertension in the rat. Am J Physiol 1995;268:L95-L100
20. Pepke-Zaba J, Higgenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-4
21. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81
22. + channel-mediated relaxation. Am J Physiol 1992;263:L88-94
23. Russell FD, Davenport AP. Characterization of endothelin receptors in the human pulmonary vasculature using bosentan, SB209670, and 97-139. J Cardiovasc Pharmacol 1995; 26(suppl 3):S346-7
24. Wanstall JC. In vitro hypoxia attenuates vasorelaxation by potassium channel opening drugs and nitroprusside in isolated pulmonary arteries from rats. J Pharmacol Exp Ther 1994;271:845-51
25. Wanstall JC. The pulmonary vasodilator properties of potassium channel opening drugs. Gen Pharmacol 1996;27: 599-605
26. Wanstall JC, O'Donnell SR. Endothelin and 5-hydroxytryptamine on rat pulmonary artery in pulmonary hypertension. Eur J Pharmacol 1990;176:159-68
27. Wanstall JC, O'Donnell SR. Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive rats. Br J Pharmacol 1992;105:152-8
28. Wilson K, Wanstall JC, Cole PH. Relaxation of human isolated pulmonary artery rings by pinacidil may not involve opening of potassium channels. Clin Exp Pharmacol Physiol 1993;suppl 1:78